{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:06:41Z","timestamp":1794658001240,"version":"4.9.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) established that targeting inflammation with interleukin-1\u03b2 (IL-1\u03b2) inhibition can significantly reduce cardiovascular (CV) event rates in the absence of any beneficial effects on cholesterol. Yet, CANTOS participants treated with both high-intensity statins and canakinumab remain at considerable risk for recurrent CV events. Both interleukin-18 (IL-18, which like IL-1\u03b2 requires the NLRP3 inflammasome for activation) and interleukin-6 (IL-6, a pro-inflammatory cytokine downstream of IL-1) may contribute to the recurrent events that occur even on canakinumab therapy, and thus represent novel targets for treating atherothrombosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Plasma samples from 4848 stable post-myocardial infarction patients who were assigned to active IL-1\u03b2 inhibition or placebo within CANTOS underwent measurement of IL-18 and IL-6 both before and after initiation of canakinumab using validated ELISA. All participants were followed over a median 3.7-year period (maximum 5\u2009years) for recurrent major adverse cardiovascular events (MACE) and for all-cause mortality. Compared to placebo, canakinumab significantly reduced IL-6 levels in a dose-dependent manner yielding placebo-subtracted median percent reductions in IL-6 at 3\u2009months of 24.8%, 36.3%, and 43.2% for the 50, 150, and 300\u2009mg doses, respectively (all P-values &amp;lt;0.001). By contrast, no dose of canakinumab significantly altered IL-18 levels measured at 3\u2009months (all effects &amp;lt;1%, all P-values\u2009&amp;gt;\u20090.05). Yet, despite these differential plasma effects, either baseline and on-treatment levels of IL-18 or IL-6 associated with rates of future CV events. For example, for MACE, each tertile increase in IL-18 measured 3\u2009months after canakinumab initiation associated with a 15% increase in risk [95% confidence interval (CI) 3\u201329%, P\u2009=\u20090.016], while each tertile increase in IL-6 measured 3\u2009months after canakinumab initiation associated with a 42% increase in risk (95% CI 26\u201359%, P\u2009&amp;lt;\u20090.0001). Similar effects were observed for MACE-plus, CV death, all-cause mortality, and the for the combination endpoint of all vascular events inclusive of revascularization procedures and hospitalization for congestive heart failure. In baseline as well as on-treatment analyses, risks were highest among those with the highest levels of both IL-18 and IL-6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There remains substantial residual inflammatory risk related to both IL-18 and IL-6 after IL-1\u03b2 inhibition with canakinumab These data support further pharmacologic development of therapies for atherothrombosis that target IL-18 or IL-6 signalling, or that can simultaneously inhibit both IL-1\u03b2 and IL-18 (such as NLRP3 inflammasome inhibitors).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT01327846.<\/jats:p>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehz542","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T15:10:21Z","timestamp":1564153821000},"page":"2153-2163","source":"Crossref","is-referenced-by-count":228,"title":["Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-4522","authenticated-orcid":false,"given":"Paul M","family":"Ridker","sequence":"first","affiliation":[{"name":"Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School , 900 Commonwealth Avenue, Boston, MA 02215, USA"},{"name":"Department of Medicine, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean G","family":"MacFadyen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School , 900 Commonwealth Avenue, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Thuren","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation, One Health Plaza , East Hanover, NJ 07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,1]]},"reference":[{"key":"2022102616072660600_ehz542-B1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102616072660600_ehz542-B2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"2022102616072660600_ehz542-B3","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102616072660600_ehz542-B4","first-page":"483","article-title":"Interleukin-18, a proinflammatory cytokine","volume":"11","author":"Dinarello","year":"2000","journal-title":"Eur Cytokine Net"},{"key":"2022102616072660600_ehz542-B5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1084\/jem.20011022","article-title":"Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis","volume":"195","author":"Gerdes","year":"2002","journal-title":"J Exp Med"},{"key":"2022102616072660600_ehz542-B6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/cvr\/cvs226","article-title":"Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis","volume":"96","author":"Badimon","year":"2012","journal-title":"Cardiovasc Res"},{"key":"2022102616072660600_ehz542-B7","doi-asserted-by":"crossref","first-page":"668.","DOI":"10.1136\/heart.84.6.668","article-title":"Interleukin 18 in acute myocardial infarction","volume":"84","author":"Seta","year":"2000","journal-title":"Heart"},{"key":"2022102616072660600_ehz542-B8","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/hc3901.096721","article-title":"Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability","volume":"104","author":"Mallat","year":"2001","journal-title":"Circulation"},{"key":"2022102616072660600_ehz542-B9","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1161\/hh0202.105292","article-title":"Interleukin-18 enhances atherosclerosis in apolipoprotein E(-\/-) mice through release of interferon-gamma","volume":"90","author":"Whitman","year":"2002","journal-title":"Circ Res"},{"key":"2022102616072660600_ehz542-B10","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/hh1901.098735","article-title":"Interleukin-18\/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability","volume":"89","author":"Mallat","year":"2001","journal-title":"Circ Res"},{"key":"2022102616072660600_ehz542-B11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0008-6363(03)00343-2","article-title":"Reduced atherosclerosis in interleukin-18 deficient apolipoprotein e-knockout mice","volume":"59","author":"Elhage","year":"2003","journal-title":"Cardiovasc Res"},{"key":"2022102616072660600_ehz542-B12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nm.3890","article-title":"Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter","volume":"21","author":"Wang","year":"2015","journal-title":"Nat Med"},{"key":"2022102616072660600_ehz542-B13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/01.CIR.0000020546.30940.92","article-title":"Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina","volume":"106","author":"Blankenberg","year":"2002","journal-title":"Circulation"},{"key":"2022102616072660600_ehz542-B14","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.0000099509.76044.A2","article-title":"Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (PRIME)","volume":"108","author":"Blankenberg","year":"2003","journal-title":"Circulation"},{"key":"2022102616072660600_ehz542-B15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.atherosclerosis.2005.12.026","article-title":"Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population. The Perth carotid ultrasound disease assessment study (CUDAS)","volume":"189","author":"Chapman","year":"2006","journal-title":"Atherosclerosis"},{"key":"2022102616072660600_ehz542-B16","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1161\/ATVBAHA.107.149484","article-title":"Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas heart study","volume":"27","author":"Zirlik","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102616072660600_ehz542-B17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102616072660600_ehz542-B18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.atherosclerosis.2005.11.013","article-title":"Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6","volume":"188","author":"Hulthe","year":"2006","journal-title":"Atherosclerosis"},{"key":"2022102616072660600_ehz542-B19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"2022102616072660600_ehz542-B20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2022102616072660600_ehz542-B21","first-page":"828","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102616072660600_ehz542-B22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"2022102616072660600_ehz542-B23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"2022102616072660600_ehz542-B24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"key":"2022102616072660600_ehz542-B25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.02.062","article-title":"All roads lead to IL-6: a central hub of cardiometabolic signaling","volume":"259","author":"Libby","year":"2018","journal-title":"Int J Cardiol"},{"key":"2022102616072660600_ehz542-B26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents. Targeting interleukin signaling pathways for the treatment of athereothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ Res"},{"key":"2022102616072660600_ehz542-B27","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"2022102616072660600_ehz542-B28","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/23\/2153\/46646666\/ehz542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/23\/2153\/46646666\/ehz542.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:09:36Z","timestamp":1666786176000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/23\/2153\/5552547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":28,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2019,9,1]]},"published-print":{"date-parts":[[2020,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz542","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,14]]},"published":{"date-parts":[[2019,9,1]]}}}